Literature DB >> 24823284

Congestive hepatopathy after Fontan operation and related factors assessed by transient elastography.

Byung Won Yoo1, Jae Young Choi2, Lucy Youngmin Eun2, Han Ki Park3, Young Hwan Park3, Seung Up Kim4.   

Abstract

OBJECTIVE: Congestive hepatopathy after a Fontan operation can have a major effect on long-term morbidity. We evaluated congestive hepatopathy in patients with Fontan circulation using transient elastography to determine which risk factors for hepatopathy are related to liver stiffness (LS).
METHODS: We evaluated 46 patients with Fontan circulation and 26 with right side heart failure (RHF) and hepatic congestion using laboratory tests, the aspartate aminotransferase-to-platelet ratio index, ultrasonography, and transient elastography.
RESULTS: The LS value was significantly greater in the Fontan group (21.1±8.0 kPa) than in the RHF group (10.0±9.0 kPa). The total bilirubin and albumin serum levels, white blood cell count, and aspartate aminotransferase to platelet ratio index correlated significantly with LS in the Fontan group. Of the risk factors, age at evaluation (r=0.42, P=.004), age at Fontan completion (r=0.51, P<.001), inferior vena cava diameter (r=0.35, P=.02), and spleen size (r=0.53, P=.002) correlated significantly with LS. Nineteen patients in the Fontan group (41.3%) had abnormal ultrasound findings, and the frequency of abnormal findings increased with increasing LS (P=.002). In the subgroup with the greatest LS value (≥30 kPa), 88.9% had abnormal ultrasound findings and 44.4% liver cirrhosis. Multivariate analysis revealed that age at Fontan procedure completion and total bilirubin were independent risk factors for hepatopathy.
CONCLUSIONS: The present study revealed that congestive hepatopathy developed in a significant fraction of patients with long-term Fontan circulation and that transient elastography could be an easy and useful method to assess congestive hepatopathy in these patients.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24823284     DOI: 10.1016/j.jtcvs.2014.04.010

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  15 in total

1.  Assessing hepatic impairment in Fontan-associated liver disease using the HepQuant SHUNT test.

Authors:  Alexander Lemmer; Lisa VanWagner; Zaira Gasanova; Steve Helmke; Gregory T Everson; Daniel Ganger
Journal:  Congenit Heart Dis       Date:  2019-08-01       Impact factor: 2.007

Review 2.  Congestive hepatopathy: Differentiating congestion from fibrosis.

Authors:  Alexander Lemmer; Lisa VanWagner; Daniel Ganger
Journal:  Clin Liver Dis (Hoboken)       Date:  2018-01-02

3.  Liver Strain Using Feature Tracking of Cine Cardiac Magnetic Resonance Imaging: Assessment of Liver Dysfunction in Patients with Fontan Circulation and Tetralogy of Fallot.

Authors:  Ryoko Ohashi; Michinobu Nagao; Umiko Ishizaki; Yumi Shiina; Kei Inai; Shuji Sakai
Journal:  Pediatr Cardiol       Date:  2019-12-18       Impact factor: 1.655

4.  Importance of dynamic central venous pressure in Fontan circulation.

Authors:  JeongHye Kim; Seiko Kuwata; Clara Kurishima; Yoichi Iwamoto; Hirotaka Ishido; Satoshi Masutani; Hideaki Senzaki
Journal:  Heart Vessels       Date:  2018-01-08       Impact factor: 2.037

Review 5.  Assessment of Advanced Liver Fibrosis and the Risk for Hepatic Decompensation in Patients With Congestive Hepatopathy.

Authors:  Alexander Lemmer; Lisa B VanWagner; Daniel Ganger
Journal:  Hepatology       Date:  2018-09-22       Impact factor: 17.425

Review 6.  Clinical applications, limitations and future role of transient elastography in the management of liver disease.

Authors:  Pik Eu Chang; George Boon-Bee Goh; Jing Hieng Ngu; Hiang Keat Tan; Chee Kiat Tan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 7.  Screening modalities for the diagnosis of Fontan-associated liver disease: evidence from the past for future development.

Authors:  Saviga Sethasathien; Krit Leemasawat; Suchaya Silvilairat; Rekwan Sittiwangkul; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

8.  Risk factors for Fontan-associated hepatocellular carcinoma.

Authors:  Tomomi Kogiso; Takaomi Sagawa; Makiko Taniai; Eriko Shimada; Kei Inai; Tokuko Shinohara; Katsutoshi Tokushige
Journal:  PLoS One       Date:  2022-06-17       Impact factor: 3.752

Review 9.  Clinical implications of organ congestion in heart failure patients as assessed by ultrasonography.

Authors:  Yoshihiro Seo; Tomofumi Nakatsukasa; Seika Sai; Tomoko Ishizu; Noriko Iida; Masayoshi Yamamoto; Tomoko Machino-Ohtsuka; Yasushi Kawakami; Akihiko Nogami; Kazutaka Aonuma
Journal:  Cardiovasc Diagn Ther       Date:  2018-02

10.  Fontan Liver Disease: Review of an Emerging Epidemic and Management Options.

Authors:  Elisa Bradley; Benjamin Hendrickson; Curt Daniels
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.